Prosecution Insights
Last updated: November 04, 2026
Application No. 18/262,535

Pharmaceutical Peptide Compositions and Methods of Preparation Thereof

Final Rejection §112
Filed
Jul 21, 2023
Priority
Jan 25, 2021 — provisional 63/141,230 +3 more
Examiner
KATAKAM, SUDHAKAR
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mylan Ireland Limited
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
977 granted / 1307 resolved
+14.8% vs TC avg
Strong +23% interview lift
Without
With
+23.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
83 currently pending
Career history
1385
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
44.6%
+4.6% vs TC avg
§102
13.0%
-27.0% vs TC avg
§112
25.4%
-14.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1307 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the application Receipt of applicant’s remarks and claim amendments filed on 08/14/2026 are acknowledged. Examiner also acknowledges applicants amendments or corrections to the specification. In light amendments to specification, previous 112(a) written description rejection is withdrawn. However, in light of amendments to specification, a new grounds of 112(a) rejection is made, see below. Claim Rejections - 35 USC § 112 – Written Description The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 17, 23-24 and 26-38 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement for the claimed method. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. The rejection is based on the requirement(s), i.e., the guidelines provided by the MPEP 2163.04. These are listed below: (A) identify the claim(s) limitations at issue, and (B) establish a prima facie case by providing reasons why a person skilled in the art at the time the application was filed would not have recognized that the inventor was in possession of the invention as claimed in view of the disclosure of the application as filed. The MPEP 2163 further provided or expanded the guidelines for the written description requirements. (A) IDENTIFY THE CLAIM LIMITATIONS AT ISSUE: First independent claim 17 and its dependent claims 23 are drawn to an aqueous stabilized peptide composition with the recited specific concentrations of the recited components, wherein the stabilizing peptide has same amino acid sequence as teduglutide and has a three amino acid truncation on the C-terminus. Dependent claim further limited to treating stabilizing peptide with a base before incorporating it into the composition. Second independent claim 24 is drawn to an aqueous stabilized peptide composition, comprising teduglutide and a stabilizing peptide, wherein the stabilizing peptide has the same amino acid sequence as teduglutide except for the following sequence alterations a truncation of 1-6 amino acids from the C-terminus. Dependent clams further limited to the recited additional components and conditions of composition. Claimed conditions or claimed limitations are associated with the property of stabilizing the teduglutide. First set of claims 17 and 23 recite specific components and their concentrations in the composition. In the second set of claims 24 and 26-38, the claimed subject matter covers a very broad technical field, which is neither supported by the examples and/or embodiment of the description, nor is disclosed in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art. Shown data is limited to a single example (see section “Teduglutide Composition Stabilized with a Stable Peptide” in [00161]-[00162] in page 33), wherein the composition comprises , teduglutide, stabilizing peptide (1-30 amino acid fragment of teduglutide, i.e., deletion of 3 amino acids from C-terminus of 33 amino acid teduglutide) and the recited components with their corresponding concentrations. Shown data may support first set of claims 17 and 23, and it cannot be extrapolated to broadly claimed subject matter of second set of claims 24 and 26-38, in absence of description or supporting evidences. However, the data shown is neither clear nor clarified nor described in such a way a skilled person can understand and can reproduce applicants claimed composition. For example, the data shown is described in Figures 4, 6 and 7, but it is not clear what exactly they represent. Both Revestive and Gattex are different tradename for teduglutide, but it is not clear why they show different pattern in Fig.4. It is also not clear what each curve represents in all Figures, since drawings are blurry and there is no description for the corresponding data in the specification. Shown example simply say samples are stable to fibril formation exhibiting a significantly increase lag time as compared to control sample. But what is control and what are curves represent is not clear. Applicants may have to show the data in table form or explain clear the shown data in the figures in their next response. Such response helps in understanding the claimed invention, specifically first set of claims 17 and 23. Further, in the second set of claims 24 and 26-38, there are no components present in the composition and the truncation can be 1-6 amino acids either from C-terminus. However, the shown data is limited to three amino acid sequence truncation on the C-terminus of teduglutide with the recited specific concentrations for the components in the composition. Further, treating the peptide is also a critical step towards the property of the composition, and independent claims do not even require this limitation. Accordingly, specification failed to describe the nexus between the shown data and claimed subject matter. In other words, the structure/function relationship for the claimed generic variables and claimed product is not described. Applicants can claim as broadly as possible for the claimed invention. However, if there is a divergency in the claimed subject matter, and if it expects unpredictability for the claimed product, then specification must describe the genus with divergent species, so that a skilled person in the art can understands claimed invention and can reproduce applicants claimed subject matter. In this case, at least protein chemistry is probably one of the most unpredictable areas of biotechnology in addition to the concentrations of components in the composition and consequently, the effects of sequence dissimilarities and other components in the composition on protein structure and function cannot be predicted. So, absence of written description with divergent species makes the invention unpredictable, and cannot be envisioned by a skilled person in the art. The MPEP lists factors that can be used to determine if sufficient evidence of possession has been furnished in the disclosure of the application. These include "level of skill and knowledge in the art, partial structure, physical and/or chemical properties, functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the method of making the claimed invention. Disclosure of any combination of such identifying characteristics that distinguish the claimed invention from other materials and would lead one of skill in the art to the conclusion that the applicant was in possession of the claimed species is sufficient" (MPEP 2163). A claimed genus may be satisfied through sufficient description of a representative number of species or disclosure of relevant, identifying characteristics such as functional characteristics coupled with a known or disclosed correlation between function and structure. See MPEP 2163 II(A)(3)(a)(ii). The number of species that describe the genus must be adequate to describe the entire genus. However, if there is substantial variability, a large number of species must be described. The question is….with regard to first set of claims 17 and 23, since data shown in not clear, and with regard to second set of claims 24 and 26-38, various additional components in the composition, in all possible combinations and concentrations, (i) did applicants provide enough description for making all possible compositions? (ii) will these be capable of retain its property? Based (i) and/or (ii), will a skilled person in the art understand the claimed invention? (B) ESTABLISH A PRIMA FACIE CASE BY PROVIDING REASONS WHY A PERSON SKILLED IN THE ART AT THE TIME THE APPLICATION WAS FILED WOULD NOT HAVE RECOGNIZED THAT THE INVENTOR WAS IN POSSESSION OF THE INVENTION AS CLAIMED IN VIEW OF THE DISCLOSURE OF THE APPLICATION AS FILED: The further analysis for adequate written description considers, see MPEP 2163, the following: (A) Determine whether the application describes an actual reduction to practice of the claimed invention: With regard to first set of claims 17 and 23: As explained above, provided description is not clear for the shown data. Applicants may have to show the data in table form or explain clear the shown data in the figures in their next response. Such response helps in understanding the claimed invention. With regard to second set of claims 24 and 26-38: Not provided. Shown data is limited to the stabilizing peptide having a 3 amino acids truncated teduglutide at C-terminus with specific concentrations of recited specific components present in the composition. No data is shown with any other components. Specification also failed to describe the nexus between the shown data and claimed subject matter. In other words, the structure/function relationship for the claimed generic variables and claimed product is not described. So, the provided data is very limited. Accordingly, applicants failed to describe actual reduction to practice of the claimed invention. (B) If the application does not describe an actual reduction to practice, determine whether the invention is complete as evidenced by a reduction to drawings or structural chemical formulas that are sufficiently detailed to show that applicant was in possession of the claimed invention as a whole: Figures 1-7 are related to the claimed subject matter. Fig.1-3 describe structure of teduglutide and comparison with other GLP sequences. Fig.4 describes ThF assay with teduglutide and stabilizing peptide with three amino acid truncation on the N-terminus. Fig.5-7 describes advantages of base treatment. So, as evidenced from the above description of drawings, it is clear that the claimed invention is not complete by a reduction to drawings or structural chemical formulas that are sufficiently detailed to show that applicant was in possession of the claimed invention as a whole. (C) If the application does not describe an actual reduction to practice or reduction to drawings or structural chemical formula as discussed above, determine whether the invention has been set forth in terms of distinguishing identifying characteristics, such as structure/function correlations, as evidenced by other descriptions of the invention that are sufficiently detailed to show that applicant was in possession of the claimed invention: Protein chemistry is probably one of the most unpredictable areas of biotechnology. Addition or deletion of amino acids and its effects cannot be envisioned. Consequently, the effects of sequence dissimilarities upon protein structure and function cannot be predicted. For example, Bowie et al (Science, 1990, 247:1306-1310) teach that an amino acid sequence encodes a message that determines the shape and function of a protein and that it is the ability of these proteins to fold into unique three-dimensional structures that allows them to function and carry out the instructions of the genome and further teaches that the problem of predicting protein structure from sequence data and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein is extremely complex (column 1, page 1306). Bowie et al further teach that while it is known that many amino acid substitutions are possible in any given protein, the position within the protein's sequence where such amino acid substitutions can be made with a reasonable expectation of maintaining function are limited. Certain positions in the sequence are critical to the three dimensional structure/function relationship and these regions can tolerate only conservative substitutions or no substitutions at all (column 2, page 1306). The sensitivity of proteins to alterations of even a single amino acid in a sequence are exemplified by Burgess et al (J. Cell Biol. 111:2129-2138, 1990) who teach that replacement of a single lysine reside at position 118 of acidic fibroblast growth factor by glutamic acid led to the substantial loss of heparin binding, receptor binding and biological activity of the protein and by Lazar et al (Mol. Cell. Biol., 8:1247-1252, 1988) who teach that in transforming growth factor alpha, replacement of aspartic acid at position 47 with alanine or asparagine did not affect biological activity while replacement with serine or glutamic acid sharply reduced the biological activity of the mitogen. These references demonstrate that even a single amino acid substitution will often dramatically affect the biological activity and characteristics of a protein. In this case, in absence of evidence, the shown data may or may not be extrapolated to the broadly claimed conditions for the claimed subject matter. In view of above, a skilled person in the art can expect unpredictability in the claimed subject matter. There are no physical/chemical/structural features that applicants have tied to the property in a relevant teaching manner, making it impossible for an individual of ordinary skill in the art to determine which of the large genus of claimed peptides and components in the composition would be effective. Without a correlation between structure and function, the claims do little more than define the claimed invention by function. That is not sufficient to satisfy the written description requirement. Applicants have failed to provide guidance or data or evidence as to how the skilled artisan would be able to extrapolate from the disclosure species to make and possibly use of the claimed invention. “A description of what a material does, rather than of what it is, usually does not suffice." Rochester, 358 F 3d at 923; Eli Lilly, 119 at 1568. Instead, the “disclosure must allow one skilled in the art to visualize or recognize the identity of the subject matter purportedly described.” Vas-Cath Inc. Mahurkar, 19 USPQ2d 1111, makes clear the "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116). Accordingly, it is deemed that the specification fails to provide adequate written description for the genus of the claimed subject matter and does not reasonably convey to one skilled in the relevant art that the inventors had possession of the entire scope of the claimed invention. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUDHAKAR KATAKAM whose telephone number is (571)272-9929. The examiner can normally be reached 8:30 am to 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUDHAKAR KATAKAM/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Jul 21, 2023
Application Filed
May 14, 2026
Non-Final Rejection mailed — §112
Aug 14, 2026
Response Filed
Oct 23, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780875
POLYPEPTIDES INCLUDING A BETA-TRICALCIUM PHOSPHATE-BINDING SEQUENCE AND USES THEREOF
3y 2m to grant Granted Nov 03, 2026
Patent 12780876
CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF
1y 1m to grant Granted Nov 03, 2026
Patent 12766196
PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS
3y 6m to grant Granted Oct 20, 2026
Patent 12760066
BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS
5y 0m to grant Granted Oct 13, 2026
Patent 12760070
CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF
1y 0m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
98%
With Interview (+23.3%)
2y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1307 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month